Drugs / Tamnorzatinib
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06532331 | Dec 2023 → Sep 2027 expected | malignant pancreatic neoplasm | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06525246 | Aug 2021 → Jun 2025 | non-small cell lung carcinoma | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03730337 | Oct 2018 → Jun 2021 | — | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03176277 | Jun 2017 → Dec 2022 | acute leukemia, myelodysplastic syndrome | Ono Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tamnorzatinib | “Tamnorzatinib (ONO-7475) is a potent and highly selective inhibitor of Axl/Mer.” PMID 41385448 ↗ Dec 2025 |
| Known as | ONO-7475 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06532331 ↗ |
| Action | Inhibit | “Tamnorzatinib (ONO-7475) is a potent and highly selective inhibitor of Axl/Mer.” PMID 41385448 ↗ Dec 2025 |
| Modality | Small molecule | — CHEMBL5314429 ↗ |